ARK Investment Acquires 509.6K Shares of Beam Therapeutics

Cathie Wood's ARK Investment has purchased 509.6K shares of Beam Therapeutics today. This investment is part of Wood's focus on biotech stocks, with her fund pouring over $46M into the sector. TipRanks Premium offers advanced data and expert analyst insights to help investors make informed decisions. Elevate your investing strategy with TipRanks at 50% off.

ARK Investment, led by renowned investor Cathie Wood, has made significant moves in the biotech sector, pouring over $46 million into the industry on Monday, August 18, 2025. The investment strategy, disclosed by ARK's ETFs, shows a strong tilt towards genomic and gene-editing stocks, while also trimming defense exposure.

One of the key purchases of the day was a $21.5 million stake in GeneDx Holdings (WGS), a health-tech company focused on DNA-based testing for rare and pediatric genetic conditions. The purchase of 170,471 shares of WGS reflects ARK's belief in the growth potential of personalized medicine. GeneDx's Q2 report showed $102.7 million in revenue and $0.50 EPS, both exceeding Wall Street estimates, further boosting confidence in the stock.

ARK also added substantial positions in other biotech companies. The ETFs purchased 176,811 shares of CRISPR Therapeutics AG (CRSP) worth $10.6 million, 395,097 shares of Beam Therapeutics (BEAM) valued at $7 million, 165,024 shares of Intellia Therapeutics (NTLA) at $6.2 million, and 28,213 shares of Pacific Biosciences of California (PACB) for $0.9 million. These trades brought ARK's biotech investments for the day to roughly $46.2 million, reinforcing its long-term focus on gene-editing and synthetic biology.

In addition to biotech stocks, ARKK purchased 123,336 shares of Robinhood Markets Inc. (HOOD), totaling $14.1 million, indicating confidence in the fintech platform.

On the sell side, ARKQ offloaded 116,364 shares of Kratos Defense and Security Solutions Inc. (KTOS) for nearly $8 million, pointing to a deliberate reduction in defense exposure.

This strategic shift towards biotech and fintech, while trimming defense exposure, aligns with ARK's long-term investment thesis. Investors should closely monitor these moves, as they may signal the fund's conviction in the growth potential of these sectors.